RMD Open

is an open access, peer-reviewed rheumatology journal that publishes original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.1
Citescore: 7.3
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

Follow the journal on X for the latest updates.

Editorial team

Vacancy: BMJ Group seeks an ambitious and dynamic Editor-in-Chief for its leading rheumatology journal, RMD Open. Please see the role description for more information on how to apply.

Application deadline: 2nd March 2025

Current Issue

Authors

RMD Open accepts submissions of a wide range of article types, including original research, analysis and practice articles, and commentaries.

The Author Information section provides specific article requirements to help you turn your work into an article suitable for RMD Open.

Information is also provided on editorial policies and open access.

Author information Submit a paper

Latest Articles

Psoriatic arthritis:

Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature

12 December 2024

Correction:

Correction: comparison of active tuberculosis occurrence associated with janus kinase inhibitors and biological DMARDs in rheumatoid arthritis

12 December 2024

Correction:

Correction: Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus

12 December 2024

Psoriatic arthritis:

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

12 December 2024

Spondyloarthritis:

Comparing the construct validity of measurement instruments for pain and stiffness in patients with axial spondyloartwhritis: cross-sectional analysis in the OASIS cohort

10 December 2024

Video Abstract

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

30 January 2024

Conclusions: Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from weeks 16 to 52.

Find out more